Format

Send to

Choose Destination
BMC Cancer. 2016 Feb 17;16:112. doi: 10.1186/s12885-016-2145-0.

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study.

Author information

1
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Singyu.moorcraft@rmh.nhs.uk.
2
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Elisa.fontana@rmh.nhs.uk.
3
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. David.cunningham@rmh.nhs.uk.
4
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Clare.peckitt@rmh.nhs.uk.
5
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Tom.waddell@rmh.nhs.uk.
6
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Elizabeth.smyth@rmh.nhs.uk.
7
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. William.allum@rmh.nhs.uk.
8
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Jeremy.thompson@rmh.nhs.uk.
9
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Sheela.rao@rmh.nhs.uk.
10
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. David.watkins@rmh.nhs.uk.
11
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Naureen.starling@rmh.nhs.uk.
12
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. ian.chau@rmh.nhs.uk.

Abstract

BACKGROUND:

Oesophagogastric adenocarcinoma (OGA) has a poor prognosis, even for patients with operable disease. However, the optimal surveillance strategy following surgery is unknown.

METHODS:

We performed a retrospective review of all patients with OGA who had undergone surgery with radical intent at the Royal Marsden between January 2001 and December 2010.

RESULTS:

Of the 360 patients with OGA who underwent potentially curative surgery, 100/214 patients (47%) with oesophageal/gastro-oesophageal junction (GOJ) adenocarcinoma and 47/146 patients (32%) with gastric adenocarcinoma developed recurrent disease. 51, 79 and 92% of relapses occurred within 1, 2 and 3 years respectively and the majority of patients relapsed at distant sites. Of the patients who relapsed, 67% (67/100) with oesophageal/GOJ adenocarcinoma and 72% of patients with gastric cancer (34/47) were symptomatic at the time of relapse. The majority of asymptomatic relapses were first detected by a rise in tumour markers. There was no difference in disease-free survival between asymptomatic and symptomatic patients, but asymptomatic patients were more likely to receive further treatment and had a longer survival beyond relapse.

CONCLUSION:

The majority of relapses occur within the first 3 years and at distant sites. Monitoring of tumour markers should be considered as part of a surveillance program.

PMID:
26883815
PMCID:
PMC4756463
DOI:
10.1186/s12885-016-2145-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center